Literature DB >> 10847484

Mast cell subpopulations in chronic inflammatory hepatobiliary diseases.

Y Matsunaga1, T Terada.   

Abstract

AIM/
BACKGROUND: In various hepatobiliary diseases mast cells have been found to be associated with fibrogenesis. However, mast cell subpopulations have not been investigated in the human liver in normal subjects or in disease. Human mast cells are categorized into mast cells positive for tryptase (MC(T)) only and mast cells positive for both tryptase and chymase (MC(TC)).
METHODS: In this study we investigated mast cell subpopulations (MC(T) and MC(TC)) by double immunostaining for mast cell tryptase and chymase as well as by a computer-aided quantitative morphometry in 13 normal livers and in 193 liver tissue specimens comprising of primary biliary cirrhosis (n=43), autoimmune hepatitis (n=11), chronic hepatitis B (n=37), chronic hepatitis C (n=41), alcoholic liver disease (n=40) and hepatolithiasis (n=21).
RESULTS: The densities of MC(T) and MC(TC) per 1 mm2 stroma were low in normal livers but high in chronic liver diseases, and correlated positively with the degree of fibrosis. The percentages of MC(T) and MC(TC) subpopulations were 25% and 75%, respectively. The percentage was almost the same in normal livers and various hepatobliliary diseases, as well as between less fibrotic cases and more fibrotic cases in liver diseases.
CONCLUSIONS: These results suggest that MC(T) and MC(TC) subpopulations in healthy and diseased livers do not change during liver fibrosis of any etiology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10847484     DOI: 10.1034/j.1600-0676.2000.020002152.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  7 in total

1.  Inhibition of mast cell-derived histamine secretion by cromolyn sodium treatment decreases biliary hyperplasia in cholestatic rodents.

Authors:  Lindsey L Kennedy; Laura A Hargrove; Allyson B Graf; Taylor C Francis; Kyle M Hodges; Quy P Nguyen; Yoshi Ueno; John F Greene; Fanyin Meng; Victoria D Huynh; Heather L Francis
Journal:  Lab Invest       Date:  2014-11-03       Impact factor: 5.662

2.  Mast cells in human bile duct obstruction.

Authors:  Maya V Gulubova; Tatyana I Vlaykova
Journal:  J Mol Histol       Date:  2004-11       Impact factor: 2.611

Review 3.  Mast cells in liver disease progression: An update on current studies and implications.

Authors:  Linh Pham; Lindsey Kennedy; Leonardo Baiocchi; Vik Meadows; Burcin Ekser; Debjyoti Kundu; Tianhao Zhou; Keisaku Sato; Shannon Glaser; Ludovica Ceci; Gianfranco Alpini; Heather Francis
Journal:  Hepatology       Date:  2021-12-12       Impact factor: 17.298

4.  Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer.

Authors:  Shi-Yun Tan; Yan Fan; He-Sheng Luo; Zhi-Xiang Shen; Yi Guo; Liang-Jia Zhao
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

Review 5.  Mast Cells in Liver Fibrogenesis.

Authors:  Ralf Weiskirchen; Steffen K Meurer; Christian Liedtke; Michael Huber
Journal:  Cells       Date:  2019-11-13       Impact factor: 6.600

Review 6.  Exploring the role of mast cells in the progression of liver disease.

Authors:  Shizhuan Huang; Haotian Wu; Feng Luo; Bin Zhang; Tianwei Li; Zongrui Yang; Bixuan Ren; Wenze Yin; Dehai Wu; Sheng Tai
Journal:  Front Physiol       Date:  2022-09-13       Impact factor: 4.755

Review 7.  The mast cell integrates the splanchnic and systemic inflammatory response in portal hypertension.

Authors:  María-Angeles Aller; Jorge-Luis Arias; Jaime Arias
Journal:  J Transl Med       Date:  2007-09-24       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.